$KYTX News

Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36

HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate

HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample

Kyverna Therapeutics shares are trading higher after the company announced longer-term follow-up data from Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis.

Kyverna Therapeutics shares are trading higher after the company announced longer-term follow-up data from Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis.

Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025; Co. May Offer Up To $100M Of Common Stock

Kyverna Therapeutics Q4 EPS $(0.80) Beats $(0.85) Estimate

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics Appoints Christi Shaw Executive Chairperson, Effective Immediately, Succeeding Ian Clark

Kyverna Therapeutics Highlights 2026 Priorities, Including Filing BLA For miv-cel in SPS in 1H And Achieve SPS Launch Readiness By Year-End

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Kyverna Therapeutics shares are trading higher after a Form 4 filing showed a Director purchased 133,333 shares at an average price of $7.50.